Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Acazicolcept (ALPN-101), a dual ICOS/CD28 antagonist, demonstrates efficacy in systemic sclerosis preclinical mouse models

Fig. 1

ICOS is increased in SSc serum. A ICOS concentration in serum from healthy controls (n = 35) and SSc patients (n = 161). B ICOS concentration in serum of SSc patients divided for diffuse/limited disease or interstitial lung disease or not. C Representative images of CD3+ and ICOS+ staining in involved skin from dcSSc of disease duration lower than 3 years and dermal skin from healthy controls (magnification × 10 and × 40). Horizontal lines represent the mean and error bars depict the standard deviation. *p < 0.05 by Student’s t test. ns = not significant

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us